NEW YORK and RESEARCH TRIANGLE PARK, N.C. , March 29, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will
Company had $120.9 million of cash and cash equivalents as of March 12, 2021 Substantial increase in liquidity driven by equity investment from Suvretta Capital and sale of Arvelle shares Company estimates it is fully funded through major upcoming milestones for GM1 gene therapy program NEW YORK
NEW YORK and RESEARCH TRIANGLE PARK, N.C. , March 11, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will
NEW YORK and RESEARCH TRIANGLE PARK, N.C. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will
- Company had $81 million of cash and cash equivalents as of December 31, 2020 , and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022 NEW YORK and RESEARCH TRIANGLE PARK, N.C. , Feb.
Company expects to receive an additional $4.8 million by mid-2021 upon approval of cenobamate in Europe, totaling over $16.4 million in aggregate net proceeds this year NEW YORK and RESEARCH TRIANGLE PARK, N.C. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc.
- First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies - Expect to continue patient identification, screening, and enrollment in Stage 1 of the study throughout 2021 NEW YORK and RESEARCH TRIANGLE PARK, N.C. , Feb.
Company to receive up to $20 million in upfront and milestone payments from non-dilutive transaction Transaction extends cash runway into 2022 NEW YORK, N.Y. and RESEARCH TRIANGLE PARK, N.C. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused
